Global Pericarditis Drugs Market Size (2024 - 2029)

Pericarditis Drugs Market Analysis

The pericarditis drugs market is expected to register a CAGR of 5.2% over the forecast period (2022-2027).

The pericarditis drugs market was substantially impacted by the COVID-19 pandemic. According to the study titled "Pericarditis in patients with COVID-19: a systematic review" published in the Journal of Cardiovascular Medicine in September 2021, COVID-19 patients with pericarditis had similar clinical features to other viral cardiotropic infections. NSAIDs and colchicine were used in half or less of the cases. Moreover, another study titled "Pericarditis after SARS-CoV-2 Infection: Another Pebble in the Mosaic of Long COVID?" published in PubMed.gov in October 2021, stated that in terms of COVID-19 and pericardial illnesses, pericarditis appears to be widespread during the acute infection but uncommon in the post-acute period, whereas minor pericardial effusions appear to be very common during the COVID-19 post-acute period. Furthermore, the study concluded that based on the findings and the delay of pericarditis, post-COVID pericarditis is linked to continuing inflammation caused by the persistence of viral nucleic acid in the pericardium without virus reproduction. As a result, glucocorticoids may be an effective treatment choice for patients that are not responding or are intolerant to conventional therapy and need to treat the pericardial inflammatory component rather than the acute viral infection. Thus, such studies highlight the growing use of pericarditis drugs among the COVID-19 patient population, in turn boosting the market growth.

Furthermore, the rise in the prevalence of cardiovascular diseases, pericarditis, and emerging therapies for pericarditis is expected to drive the market growth for pericarditis drugs. According to the July 2021 update by the World Health Organization, cardiovascular diseases are the leading cause of death around the world, including diseases such as coronary heart disease, cerebrovascular disease, rheumatic heart disease, congenital heart disease, and others. As per the same source, 17.9 million people around the world died from cardiovascular diseases, which amounted to about 32% of all global deaths. This high prevalence of cardiovascular diseases and deaths associated with it are expected to drive the market growth of pericarditis drugs, as pericarditis is often linked to cardiac surgeries and heart attacks. Furthermore, the data published by American Heart Association in April 2021 stated that pericarditis affects people of all ages. However, it is more common in men aged 16 to 65. Up to 30% of patients treated for acute pericarditis may acquire the condition again, with a small proportion acquiring chronic pericarditis.

Moreover, according to the study titled "US Database Study of Clinical Burden and Unmet Need in Recurrent Pericarditis," published in the Journal of American Heart Association in July 2021, the annual incidence of acute pericarditis is approximately 27.7 per 100,000 people. After the first episode, nearly 30% of patients experience disease recurrence. In developed countries, the mortality rate of acute pericarditis is around 1.1%. Thus, the rising prevalence of pericarditis is anticipated to boost the market growth over the forecast period.

Additionally, clinical trials are being conducted for the treatment of pericarditis to develop newer therapeutic drugs. For instance, according to ClinicalTrials.gov Updates in May 2021, a trial titled "A Pilot Study of KPL-914 in Recurrent Pericarditis" under the Phase II development is examining the preliminary efficacy and safety of KPL-914 treatment in participants with recurrent pericarditis. Similarly, according to the ClinicalTrials.gov updates in October 2021, the trial titled "Dexamethasone Compared to Non-steroidal Anti-inflammatory Drugs in the Treatment of Acute Pericarditis (Dexa-P)" is under phase IV development for assessing the use of dexamethasone as an alternative to NSAID for use in patients with acute pericarditis. Thus, growing clinical development activities by key market players are anticipated to drive the market over the forecast period.

However, side effects associated with pericarditis drugs are likely to restrain the market growth over the forecast period.

Pericarditis Drugs Industry Segmentation

Pericarditis is an inflammation of the pericardium. Pericardial effusion is an inflammation that develops around the heart's lining, resulting in chest discomfort and fluid buildup around the heart. Pericarditis can be acute or chronic. The pericarditis drugs market by drug type (nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, others), distribution channel (hospital pharmacies, retail pharmacies, online pharmacies), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above-mentioned segments.